Agomab Therapeutics
Antwerp, BE · Founded 2017 · 74 employees on LinkedIn · 12 known investors
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
Founders & leadership
TK
Tim KnotnerusinChief Executive Officer
Investors · 12
EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M
AdBio partnersParis
Andera PartnersParis
Asabys PartnersMadrid
Canaan PartnersStamford · $500K – $20M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
V-Bio VenturesGhent · $270K – $2.2M
Fidelity InvestmentsreportedBoston
Also in the syndicate · 4
CanaanDawn BiopharmaPfizerleadWalleye Capital
Funding
SEC filings, press & company announcements- Undisclosed amountSeries COct 2023
Fidelity Management & Research (lead), Canaan, Dawn Biopharma, EQT Life Sciences
Source ↗ - Undisclosed amountseries B extensionJul 2022
Pfizer (lead), Asabys Partners, Walleye Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 4
by search overlap
Adimab12 shared keywordsAdimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system. The company partners with biopharma firms to accelerate the development of transformative protein therapeutics from discovery through clinical progression.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
EquityZen6 shared keywordsEquityZen operates an online marketplace that gives accredited individual investors access to shares in late-stage private companies through secondary market transactions. Now part of Morgan Stanley, the platform provides private market data, offering documents, and guided investment processes for buying and selling pre-IPO equity.
Robinhood6 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Agomab Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Agomab Therapeutics do?
- Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
- Who are Agomab Therapeutics's investors?
- Agomab Therapeutics's investors include EQT Life Sciences, AdBio partners, Andera Partners, Asabys Partners, Canaan Partners, Pontifax Venture Capital, V-Bio Ventures, Fidelity Investments.
- Where is Agomab Therapeutics headquartered?
- Agomab Therapeutics is headquartered in Antwerp, BE.